Disruption has been the norm for many businesses in 2020 thanks to the COVID-19 pandemic. This disruption worked to the detriment of most companies. But for some, the changing dynamics brought by the coronavirus outbreak have been positive catalysts. You can put BioNTech (NASDAQ: BNTX) and Emergent BioSolutions (NYSE: EBS) firmly in the latter category.
BioNTech stock skyrocketed more than 630% year to date in July before giving up some of its gains. Shares of the German biotech are still up 115% so far in 2020 thanks to intense interest in its novel coronavirus vaccine candidate. Emergent BioSolutions stock has soared nearly 140% year to date due to its COVID-19 programs.
Which of these two stocks is the better pick now? Here's how BioNTech and Emergent BioSolutions stack up against each other.